45 results
8-K
EX-99.2
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
through Q3 2024, inclusive of Phase 3 planning and preparatory activities. Q1 2024 R&D Expense $7.2M G&A Expense $3.8M Net Loss $10.4M Cash
8-K
EX-99.1
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
and preparatory activities.
R&D Expenses – Research and development expenses for the quarter ended March 31, 2024 were $7.2 million, an increase of $2.9
8-K
EX-99.2
LUMO
Lumos Pharma Inc
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
to advancing the PGHD program into Phase 3 Year 2023 Year 2022 R&D Expense $22.1M $17.9M G&A Expense $16.6M $15.7M Net Loss $34.0M $31.1M Cash, Cash
8-K
EX-99.1
LUMO
Lumos Pharma Inc
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
. Cash on hand as of December 31, 2023 is expected to support operations through the third quarter of 2024.
R&D Expenses – Research and development
8-K
EX-99.1
zere2bokjpx vkqhf
7 Nov 23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
4:42pm
8-K
EX-99.1
jrnndwy8 ojira442
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
EX-99.1
gf5na9l7r983
3 May 23
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
4:49pm
8-K
EX-99.1
eg9a5hd2 bi3gv
14 Nov 22
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
7:29am
8-K
EX-99.2
1wtzv6g8c8e4vzm 9f
14 Nov 22
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
6:55am
8-K
EX-99.1
ydg9ptm
10 Aug 22
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
12:00am
8-K
EX-99.1
roz 5cawtbc51eqqmr
10 May 22
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
4:47pm
8-K
EX-99.1
c4c4 46ikf
10 Mar 22
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
4:20pm
8-K
EX-99.1
e9n0cglqw7cz4 3n1
3 Nov 21
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
4:11pm
8-K
EX-99.1
km52g5 z0vyv21ae8
5 Aug 21
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
4:27pm
8-K
EX-99.2
ak44bvtu
5 Aug 21
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
4:27pm
8-K
EX-99.1
hovsy09ljrw08bqoyr
5 May 21
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
4:28pm
8-K
EX-99.1
z69fc6jrzhpvrj
9 Mar 21
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
4:26pm